Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
MEIJER, INC. et al v. BIOVAIL CORPORATION et al
Case Number:
2:08-cv-02431
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Ballard Spahr
- Berger Montague
- Cohen Milstein
- Covington & Burling
- Desmarais LLP
- Faruqi & Faruqi
- Gibson Dunn
- Hagens Berman
- Kirkland & Ellis
- NastLaw
- Radice Law Firm
- Spector Roseman
- Sperling & Slater
- Taus Cebulash
- Troutman Pepper
- Tucker Law Group
Companies
Government Agencies
Sectors & Industries:
-
September 23, 2015
GSK Gets Wellbutrin Pay-For-Delay Antitrust Suit Nixed
A Pennsylvania federal judge nixed claims from consumers and wholesalers Wednesday that GlaxoSmithKline paid off generic rivals to keep cheaper versions of antidepressant Wellbutrin XL off the market, ruling that buyers couldn't show that the settlements that let the patent challenge continue violated antitrust law.
-
August 05, 2015
Decertification Appealed In Wellbutrin Pay-For-Delay Suit
A class of indirect purchasers in the pay-for-delay litigation against GlaxoSmithKline PLC and others over the antidepressant Wellbutrin XL appealed its decertification to the Third Circuit last week after a Pennsylvania federal judge said it hadn't shown the class was ascertainable.
-
February 15, 2013
Valeant Pays $12M To Settle Wellbutrin Antitrust Claims
Valeant Pharmaceuticals International Inc. will pay at least $11.75 million to settle a class action brought by health insurers and other indirect purchasers, accusing it of conspiring to stifle generic versions of antidepressant Wellbutrin XL and monopolize the market, according to documents filed Friday in Pennsylvania federal court.
-
July 23, 2012
Biovail Puts Up $37.5M To Ditch Wellbutrin Antitrust Case
Biovail Corp., now part of Valeant Pharmaceuticals International Inc., agreed to pay $37.5 million Monday to settle direct purchasers' claims in antitrust multidistrict litigation alleging it conspired to stifle the market for a generic version of antidepressant Wellbutrin XL.
-
August 15, 2011
Indirect Purchasers Certified In Wellbutrin Antitrust Suit
A Pennsylvania federal judge on Monday granted class certification to a group of indirect purchasers of Wellbutrin XL and its generic equivalent in a suit that accuses drugmakers Biovail Corp. and GlaxoSmithKline PLC of lodging baseless patent suits to delay the generic competition for the popular antidepressant.